Creative Biolabs has announced an expansion of its advanced single-cell multi-omics and RNA sequencing solutions, aiming to meet the growing demand for high-resolution cellular profiling in biomedical research. The upgraded suite provides end-to-end services, from single-cell transcriptome profiling to integrated multimodal and multi-omics workflows, supporting global researchers across oncology, immunology, and neuroscience. This development matters because it addresses critical barriers in single-cell analysis, such as processing complex or archived samples, and enables a more comprehensive understanding of cellular heterogeneity and disease mechanisms.
As life science research shifts from bulk tissue profiling to single-cell resolution, dissecting cellular heterogeneity has become essential for identifying rare cell subpopulations, characterizing complex tumor microenvironments, and tracing cell lineage trajectories. To support these pipelines, Creative Biolabs offers robust, high-throughput single-cell RNA sequencing services that provide high sensitivity and coverage across thousands of individual cells, delivering high-resolution transcriptomic insights from diverse fresh biological specimens.
The platform also features specialized single-nucleus RNA sequencing (snRNA-seq) capabilities to address the long-standing challenge of processing complex, fibrous, or biobanked archival samples. For tissues where single-cell dissociation is prone to cell damage, dissociation-induced stress responses, or selective loss of fragile cell types—such as human brain, myocardium, or flash-frozen clinical biopsies—Creative Biolabs provides an optimized single-cell nuclei RNA sequencing service. By isolating intact nuclei, this approach bypasses harsh enzymatic dissociation while minimizing dissociation-related artifacts and retaining informative nuclear RNA profiles, dramatically expanding the scope of clinical translational research.
Recognizing that cellular identity is orchestrated across multiple regulatory layers, Creative Biolabs goes beyond single-dimensional analysis by advancing its high-throughput single-cell multi-omics service. This integrated platform allows the simultaneous interrogation of genomic variations, epigenomic landscapes (e.g., chromatin accessibility), cell surface proteomics (CITE-seq), and transcriptomes within identical single cells. By directly linking epigenetic regulation and genomic alterations to gene expression readouts, the service enables researchers to construct multi-dimensional cellular atlases and uncover novel therapeutic targets with unprecedented biological clarity.
"Understanding biology at single-cell and single-nucleus resolution is no longer a luxury—it is fundamental to precision medicine and biomarker discovery," said a senior scientist at Creative Biolabs. "Our goal is to provide researchers with a seamless, modular analytical ecosystem that transforms difficult biological samples into reliable, high-dimensional datasets with rigorous bioinformatics support." This perspective underscores the growing recognition that single-cell technologies are indispensable for modern biomedical research, particularly as precision medicine demands increasingly detailed cellular maps.
Supported by advanced microfluidics technologies, stringent quality control benchmarks, and tailored bioinformatics pipelines, Creative Biolabs continues to partner with academic and biopharmaceutical research teams worldwide to unravel the complexities of human disease. The implications of this expansion are significant: by making single-cell and single-nucleus sequencing more accessible and reliable, Creative Biolabs is empowering researchers to tackle previously intractable biological questions, potentially accelerating the development of new diagnostics and therapeutics. As the field moves toward multi-omics integration, such comprehensive solutions will be crucial for translating cellular insights into clinical breakthroughs.
